Dennler HJ - Search Results

1

Inhibition of pancreatic secretion under long-term octreotide treatment in humans.

Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, Büchler MW. Friess H, et al. Among authors: dennler hj. Digestion. 1994;55 Suppl 1:10-5. doi: 10.1159/000201182. Digestion. 1994. PMID: 8132133

2

Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis.

Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, Büchler MW. Friess H, et al. Among authors: dennler hj. Br J Surg. 1995 Sep;82(9):1270-3. doi: 10.1002/bjs.1800820938. Br J Surg. 1995. PMID: 7552016 Clinical Trial.

3

Treatment of advanced pancreatic cancer with high-dose octreotide.

Friess H, Büchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG. Friess H, et al. Among authors: dennler hj. Int J Pancreatol. 1993 Dec;14(3):290-1. doi: 10.1007/BF02784939. Int J Pancreatol. 1993. PMID: 8113631 No abstract available.

4

Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.

Friess H, Büchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG. Friess H, et al. Among authors: dennler hj. Pancreas. 1993 Sep;8(5):540-5. doi: 10.1097/00006676-199309000-00002. Pancreas. 1993. PMID: 8302789

5

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ. Arnold R, et al. Among authors: dennler hj. Gut. 1996 Mar;38(3):430-8. doi: 10.1136/gut.38.3.430. Gut. 1996. PMID: 8675099 Free PMC article. Clinical Trial.

6

The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.

Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, Bruns C, Joseph K, Arnold R. Trautmann ME, et al. Among authors: dennler hj. Horm Metab Res Suppl. 1993;27:24-7. Horm Metab Res Suppl. 1993. PMID: 8392487 Clinical Trial. No abstract available.

7

[Hydergin therapy of cerebrovascular insufficiency in patients requiring digitalis. Results of a double-blind study (author's transl)].

Dennler HJ, Bachmann H. Dennler HJ, et al. MMW Munch Med Wochenschr. 1979 Nov 30;121(48):1615-8. MMW Munch Med Wochenschr. 1979. PMID: 118360 Clinical Trial. German.

8

The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Dominiak P, Grevel J, Abisch E, Grobecker H, Dennler HJ, Welzel D. Dominiak P, et al. Among authors: dennler hj. Eur J Clin Pharmacol. 1988;35(1):53-7. doi: 10.1007/BF00555507. Eur J Clin Pharmacol. 1988. PMID: 3146506 Clinical Trial.

9

Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients.

Sörgel F, Abisch E, Dennler HJ, Lang E. Sörgel F, et al. Among authors: dennler hj. Eur J Clin Pharmacol. 1984;26(1):133-5. doi: 10.1007/BF00546722. Eur J Clin Pharmacol. 1984. PMID: 6714287 Clinical Trial.

10

[Co-dergocrinmesylate in elderly hypertensive patients].

Bock KD, Welzel D, Dennler HJ. Bock KD, et al. Among authors: dennler hj. MMW Munch Med Wochenschr. 1982 Dec 3;124(48):1095-8. MMW Munch Med Wochenschr. 1982. PMID: 6817133 Clinical Trial. German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters